A Study of LY3463251 in Healthy Participants
| Status: | Recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/25/2019 |
| Start Date: | December 6, 2018 |
| End Date: | September 21, 2020 |
| Contact: | This is a single site clinical trial. 1-877-CTLILLY (1-877-285-4559) or |
| Email: | ClinicalTrials.gov@lilly.com |
| Phone: | 1-317-615-4559 |
A Randomized, Placebo-Controlled, Subject- and Investigator-Blind, Single and Multiple Dose, Safety, Tolerability, and Pharmacokinetics Study of LY3463251 in Healthy and Overweight Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability (side effects) of single
(Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously
(under the skin) into the abdomen.
This is a two-part study. Participants will enroll in only one part. For each participant,
Part A will last about 10 weeks and Part B will last about 13 weeks, including screening.
(Part A) and multiple (Part B) doses of the study drug when it is administered subcutaneously
(under the skin) into the abdomen.
This is a two-part study. Participants will enroll in only one part. For each participant,
Part A will last about 10 weeks and Part B will last about 13 weeks, including screening.
Inclusion Criteria:
- Healthy males and females
Exclusion Criteria:
- Diagnosed with Type 1 or Type 2 diabetes
- Women who are of childbearing potential or who are breastfeeding
- Donated blood of more than 500 millilitres (mL) within the previous 3 months of study
screening
- Have used any tobacco product within 3 months of Day -1, or are unwilling to refrain
from the use of tobacco during the study
We found this trial at
1
site
Daytona Beach, Florida 32117
Principal Investigator: Lawrence A Galitz
Phone: 386-257-5717
Click here to add this to my saved trials
